RNA Therapeutics in Cardiovascular Precision Medicine

Frontiers in Physiology
Ageliki LainaKonstantinos Stellos


Since our knowledge on structure and function of messenger RNA (mRNA) has expanded from merely being an intermediate molecule between DNA and proteins to the notion that RNA is a dynamic gene regulator that can be modified and edited, RNA has become a focus of interest into developing novel therapeutic schemes. Therapeutic modulation of RNA molecules by DNA- and RNA-based therapies has broadened the scope of therapeutic targets in infectious diseases, cancer, neurodegenerative diseases and most recently in cardiovascular diseases as well. Currently, antisense oligonucleotides (ASO), small interfering RNAs (siRNAs), and microRNAs are the most widely applied therapeutic strategies to target RNA molecules and regulate gene expression and protein production. However, a number of barriers have to be overcome including instability, inadequate binding affinity and delivery to the tissues, immunogenicity, and off-target toxicity in order for these agents to evolve into efficient drugs. As cardiovascular diseases remain the leading cause of mortality worldwide, a large number of clinical trials are under development investigating the safety and efficacy of RNA therapeutics in clinical conditions such as familial hypercholesterolemia, di...Continue Reading


Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·M W CarrT A Springer
Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·Z Dominski, R Kole
Apr 15, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·T E Strandberg, R S Tilvis
May 11, 2000·Proceedings of the National Academy of Sciences of the United States of America·C WahlestedtJ Wengel
May 12, 2000·Biochimica Et Biophysica Acta·S T Crooke
Sep 6, 2002·Nature·Christopher P RusconiBruce A Sullenger
Aug 28, 2003·Nature Cell Biology·Carol A SledzBryan R G Williams
Jul 31, 2004·Science·Jidong LiuGregory J Hannon
Dec 31, 2004·The New England Journal of Medicine·Evangelos S GragoudasUNKNOWN VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group
Mar 7, 2006·Nature Reviews. Drug Discovery·Eugene W M NgAnthony P Adamis
May 17, 2006·Clinical and Experimental Pharmacology & Physiology·Jasmine H P ChanW S Fred Wong
May 19, 2007·Science·Philipp KapranovThomas R Gingeras
Mar 26, 2008·Archives of Internal Medicine·Anna BennetVilmundur Gudnason
Jan 23, 2009·Nature·Haruhiko Siomi, Mikiko C Siomi
Feb 4, 2009·Nature Reviews. Genetics·Tim R MercerJohn S Mattick
Dec 22, 2009·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Gregory M MarcusJeffrey E Olgin
Jan 1, 2010·Nature Reviews. Drug Discovery·Aimee L Jackson, Peter S Linsley
Mar 10, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Shaker A Mousa, Shaymaa S Mousa
Oct 23, 2010·European Heart Journal·Børge G NordestgaardUNKNOWN European Atherosclerosis Society Consensus Panel
Mar 23, 2011·Nature Genetics·Susanna ObadSakari Kauppinen
Jun 8, 2011·The Journal of Clinical Investigation·Katey J RaynerKathryn J Moore
Aug 5, 2011·Nucleic Acids Research·Rimantas SapranauskasVirginijus Siksnys
Jan 21, 2012·Nature Reviews. Drug Discovery·Ryszard KoleSidney Altman
Jun 30, 2012·Science·Martin JinekEmmanuelle Charpentier
Sep 28, 2012·British Journal of Clinical Pharmacology·Stanley T Crooke, Richard S Geary
Oct 11, 2012·Proceedings of the National Academy of Sciences of the United States of America·Bianca C BernardoJulie R McMullen
Oct 25, 2012·The Journal of Clinical Investigation·Yukti ChoudhuryShu Wang
Jan 5, 2013·Science·Le CongFeng Zhang
Jan 5, 2013·Science·Prashant MaliGeorge M Church
Jan 8, 2013·Nature Medicine·Leilei ChenXin-Yuan Guan
Mar 29, 2013·The New England Journal of Medicine·Harry L A JanssenMichael R Hodges
May 11, 2013·Arteriosclerosis, Thrombosis, and Vascular Biology·Marius R RobciucMatti Jauhiainen
May 15, 2013·Journal of Lipid Research·Philipp WiesnerYury I Miller
May 25, 2013·Circulation Research·Murray W Huff, Robert A Hegele
Jun 5, 2013·Nature Reviews. Genetics·Gunter Meister
Aug 3, 2013·Annals of Neurology·Jerry R MendellUNKNOWN Eteplirsen Study Group

❮ Previous
Next ❯


May 31, 2019·Circulation Research·Paula Ortiz-SánchezEnrique Lara-Pezzi
Jun 15, 2019·Journal of Cellular and Molecular Medicine·Xiaofei LiNiancai Peng
May 29, 2019·Current Opinion in Lipidology·Preetha Shridas, Lisa R Tannock
Dec 7, 2019·Science Advances·Chakkrapong HandumrongkulRobert Debs
Jan 30, 2020·RNA Biology·Phensinee HaruehanroengraJia Sheng
Jan 18, 2020·Non-coding RNA·Maral AzodiEmma Louise Robinson
Mar 20, 2020·European Journal of Preventive Cardiology·Dan GaitaAdelina Mihaescu
Feb 23, 2019·Arteriosclerosis, Thrombosis, and Vascular Biology·Ann Marie Schmidt
Apr 29, 2020·International Journal of Molecular Sciences·Siran ZhuGracjan Michlewski
Jun 5, 2020·Current Atherosclerosis Reports·Alberico L CatapanoGiuseppe D Norata
Mar 3, 2020·Frontiers in Pharmacology·Drew NassalThomas J Hund
Jun 20, 2020·Journal of Internal Medicine·A van der PolP van der Meer
Apr 8, 2020·Mediators of Inflammation·Xiaona XuGuangping Li
Aug 20, 2020·Circulation. Genomic and Precision Medicine·Saumya DasUNKNOWN American Heart Association Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular B
Apr 15, 2021·Hellenic Journal of Cardiology : HJC = Hellēnikē Kardiologikē Epitheōrēsē·Simon Tual-Chalot, Konstantinos Stellos
Apr 24, 2021·World Journal of Diabetes·Jake RajbhandariJoseph M Pappachan
May 7, 2021·Cardiovascular Research·Rajesh KumariSuresh Kumar Verma
Jul 25, 2021·Journal of Molecular and Cellular Cardiology·Nikolaos I VlachogiannisKonstantinos Stellos
Jun 20, 2020·The Journal of Physical Chemistry Letters·Lev Levintov, Harish Vashisth
Nov 14, 2021·Proceedings of the National Academy of Sciences of the United States of America·Alisha ChitrakarAlexei Korennykh

❮ Previous
Next ❯

Methods Mentioned

antisense oligonucleotides
chemical modifications
antisense oligonucleotide
Exome Sequencing

Clinical Trials Mentioned


Software Mentioned


Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiac Amyloidosis

Cardiac amyloidosis is a myocardial disease characterized by extracellular amyloid infiltration throughout the heart. Discover the latest research on cardiac amyloidosis here.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Antisense Oligonucleotide Therapies: ND

Antisense oligonucleotides are synthetic DNA oligomers that hybridize to a target RNA. This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases.

Related Papers

Nature Reviews. Endocrinology
Michael P CzechGregory J Tesz
Postdoc Journal : a Journal of Postdoctoral Research and Postdoctoral Affairs
Jessica Chery
© 2021 Meta ULC. All rights reserved